January 15, 2021 07:30 AM EST
R&D

Can Brett Mo­nia push Io­n­is be­yond Spin­raza?

Jason Mast

Editor

For 30 years, Brett Mo­nia strug­gled as one of Io­n­is’ top sci­en­tists to get their an­ti­sense tech­nol­o­gy to work. Now, as CEO, he’s try­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times